Program
GENSCI148
A development code. Also written as “GenSci148 Injection”.
Its studies are mostly in Retinal Vein Occlusion, led by Changchun GeneScience Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Changchun GeneScience Pharmaceutical | 11 open or running | phase 1since Sep 2, 2026 | Sep 2, 2026 | Jun 2028phase 1 · NCT07817615 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 2, 2026First study: phase 1 study in Retinal Vein OcclusionFirst studyNCT07817615 · 60 planned · China
Ahead
- Jun 2028Primary completion: phase 1 study in Retinal Vein OcclusionNCT07817615
TargetBeta
“GenSci148 is a fusion protein that simultaneously targets VEGF-A, VEGF-C, VEGF-D, and Ang-2.”study text, by rule · the study
Other programs on ANGPT2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| faricimabrule | Hoffmann-La Roche | phase 4 | 17 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07817615Retinal Vein Occlusion · China | 1 | Not yet recruiting | Jun 2028 | 60 |
How it is read
Names in the registry
- “GenSci148 Injection”, 1 entry
Codes read as this program: GENSCI148.
Conditions, from the studies’ own filings
- Retinal Vein Occlusion, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.